Back
TriMas Corp. 10K Form
Buy
67
TRS
TriMas Corp.
Last Price:
$33.27
Seasonality Move:
4.72%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
| 2024-04-30 | 10Q | TRS/TriMas Corp. Quarterly |
| 2023-10-26 | 10Q | TRS/TriMas Corp. Quarterly |
| 2023-07-27 | 10Q | TRS/TriMas Corp. Quarterly |
| 2023-04-27 | 10Q | TRS/TriMas Corp. Quarterly |
| 2022-10-27 | 10Q | TRS/TriMas Corp. Quarterly |
| 2022-07-28 | 10Q | TRS/TriMas Corp. Quarterly |
Receive TRS News And Ratings
See the #1 stock for the next 7 days that we like better than TRS
TRS Financial Statistics
Sales & Book Value
| Annual Sales: | $925M |
|---|---|
| Cash Flow: | $22.8M |
| Price / Cash Flow: | 30.92 |
| Annual Sales: | $17.84 |
| Price / Book: | 1.88 |
Profitability
| EPS (TTM): | 1.07550 |
|---|---|
| Net Income (TTM): | $44.1M |
| Gross Margin: | $185.4M |
| Return on Equity: | 6.34% |
| Return on Assets: | 3.16% |
TriMas Corp. Earnings Forecast
Key TriMas Corp. Financial Ratios
-
The Gross Profit Margin over the past 37 years for TRS is 20.04%.
-
The Selling, General & Administrative Expenses for TRS have been equal to 16.54% of Gross Profit Margin.
-
The Research & Development expenses have been 0.08% of Revenue.
-
The Interest Expense is 80.66% of Operating Income.
-
The Net Earning history of TRS is 2.62% of Total Revenues.
-
Per Share Earnings over the last 37 years have been positive in 18 years.
TriMas Corp. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Containers & Packaging |
| Sector: | Materials |
| Current Symbol: | TRS |
| CUSIP: | 896215 |
| Website: | trimas.com |
Debt
| Debt-to-Equity Ratio: | 0.63 |
|---|---|
| Current Ratio: | 2.68 |
| Quick Ratio: | 1.27 |
Price-to-Earnings
| Trailing P/E Ratio: | 56.68 |
|---|---|
| Forward P/E Ratio: | 18.06 |
TRS Technical Analysis vs Fundamental Analysis
Buy
67
TriMas Corp. (TRS)
is a Buy
Is TriMas Corp. a Buy or a Sell?
-
TriMas Corp. stock is rated a BuyThe current TriMas Corp. [TRS] share price is $33.48. The Score for TRS is 67, which is 34% above its historic median score of 50, and infers lower risk than normal.